Jones Financial Companies Lllp Raises Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Jones Financial Companies Lllp boosted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 9.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 17,414 shares of the company’s stock after buying an additional 1,514 shares during the period. Jones Financial Companies Lllp’s holdings in Hims & Hers Health were worth $421,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HIMS. State Street Corp increased its position in shares of Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Geode Capital Management LLC increased its holdings in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares in the last quarter. Wellington Management Group LLP raised its position in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the period. Yong Rong HK Asset Management Ltd acquired a new position in shares of Hims & Hers Health during the fourth quarter worth about $41,104,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Hims & Hers Health by 15.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $34.34 on Tuesday. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The company has a fifty day moving average price of $37.83 and a two-hundred day moving average price of $27.73. The company has a market cap of $7.63 billion, a PE ratio of 78.04 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. BTIG Research started coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Citigroup reiterated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday, March 6th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Bank of America reiterated an “underperform” rating and issued a $21.00 price target on shares of Hims & Hers Health in a research note on Thursday, March 6th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $37.23.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares in the company, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 78,127 shares of Hims & Hers Health stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the sale, the chief executive officer now directly owns 109,956 shares in the company, valued at approximately $3,256,896.72. This trade represents a 41.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 969,191 shares of company stock worth $34,005,375. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.